Halozyme to develop subcutaneous versions of BMS immuno-oncology drugs
Using its Enhanze technology, Halozyme Therapeutics Inc. agreed to develop subcutaneous formulations of Bristol-Myers Squibb Co.'s immuno-oncology drugs.
- Drug Delivery
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.